Publications

Rising Documented Use of Unapproved BPC-157 and Associated Patient-Reported Outcomes Curated from Clinical Notes

This study describes documented use and reported outcomes; it establishes neither efficacy nor safety and motivates rigorous prospective evaluation.

Leading the Conversation in Healthcare AI

Biology Methods and Protocols
Preprints.org
npj Metabolic Health and Disease
Biology Methods and Protocols
npj Gut and Liver
PNAS Nexus
The Breast Journal
Pulmonary Circulation
medRxiv
BMC Medical Informatics and Decision Making
nference Publications
Current Medical Research and Opinion
Cancers
JMIR Cancer
Journal of Clinical Neuroscience
JCO Oncology Practice
AMCP Nexus
European Respiratory Journal
PLOS ONE
iScience
eClinicalMedicine
Clinical and Translational Gastroenterology
EASL SLD Summit
Journal of Clinical Oncology
Scientific Reports
Vaccines
The Lancet Digital Health
JAMA Network Open
Cell Death Discovery
Molecular Systems Biology
Journal of Clinical Investigation
npj Digital Medicine
Journal of Stroke and Cerebrovascular Diseases
Genes
bioRxiv
Scientific Reports
eLife
Clinical Cancer Research
Journal of Thoracic Oncology
Biology Methods and Protocols
Preprints.org
npj Metabolic Health and Disease
Biology Methods and Protocols
npj Gut and Liver
PNAS Nexus
The Breast Journal
Pulmonary Circulation
medRxiv
BMC Medical Informatics and Decision Making
nference Publications
Current Medical Research and Opinion
Cancers
JMIR Cancer
Journal of Clinical Neuroscience
JCO Oncology Practice
AMCP Nexus
European Respiratory Journal
PLOS ONE
iScience
eClinicalMedicine
Clinical and Translational Gastroenterology
EASL SLD Summit
Journal of Clinical Oncology
Scientific Reports
Vaccines
The Lancet Digital Health
JAMA Network Open
Cell Death Discovery
Molecular Systems Biology
Journal of Clinical Investigation
npj Digital Medicine
Journal of Stroke and Cerebrovascular Diseases
Genes
bioRxiv
Scientific Reports
eLife
Clinical Cancer Research
Journal of Thoracic Oncology

Browse nference's publication below

Therapeutic Areas
Study Type
Publication Year
Newest First

BPC-157 Gray-market therapeutics Clinical-note surveillance

November 5, 2026

Rising Documented Use of Unapproved BPC-157 and Associated Patient-Reported Outcomes Curated from Clinical Notes

This study describes documented use and reported outcomes; it establishes neither efficacy nor safety and motivates rigorous prospective evaluation.

Biology Methods and Protocols

Neurosensory outcomes

GLP-1

November 4, 2026

Somatosensory and peripheral neuropathic outcomes after semaglutide or tirzepatide initiation compared with other anti-diabetic medications

In this observational study we found no evidence of a population-level excess of documented somatosensory or peripheral neuropathic phenotypes after semaglutide or tirzepatide initiation; the modestly lower incidence was within the range of systematic error indicated by the negative controls.

Biology Methods and Protocols

Zepbound

weight loss

October 21, 2026

Excessive Weight Loss with Zepbound Is Associated with Higher Rates of Adverse Events, Electrolyte Imbalances, and Hospitalization than Moderate Weight Loss

While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation.

Preprints.org

October 20, 2026

Menopause Hormone Therapy and Weight Loss Response to GLP-1–Based Therapies in Midlife Women: A Retrospective Cohort Study

In this large real-world cohort of midlife women treated for overweight or obesity, concomitant HT was associated with significantly greater and sustained weight loss with SEM. A similar directional effect with TZP was observed at early timepoints but did not reach statistical significance. Larger prospective studies are warranted to confirm these observations and to inform individualized treatment strategies in midlife women.

semaglutide

pregnancy

October 16, 2026

Continuing Semaglutide into the First Trimester of Pregnancy Is Not Associated with Maternal or Newborn Complications in Routine Care

Overall, semaglutide prescribing during pregnancy was not associated with significant differences in maternal or newborn outcomes studied in this routine care setting.

Preprints.org

Oral semaglutide

Orforglipron

September 28, 2026

Oral Wegovy is associated with greater early weight loss than Foundayo in propensity matched adult GLP-1 users

In a small subset with 90-day follow-up weights, oral Wegovy was associated with greater early weight loss than Foundayo; comparative safety findings remain exploratory.

Preprints.org

Oral semaglutide

Weight-loss response

September 20, 2026

Oral GLP-1 Super-Responders are Characterized by Greater Pretreatment Weight Gain, Faster Early Dose Escalation, and Larger On-Treatment Blood Pressure Reductions

Greater early weight loss tracked prior weight gain, faster dose escalation, and larger blood-pressure reductions.

Preprints.org

Incretin therapies

Kidney biomarkers

September 3, 2026

Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication Opportunities

The study explored organ-specific biomarker patterns across metabolic therapies.

Preprints.org

of 13